Atypical Antipsychotics in Improvement of Quality of Life in Bipolar Disorder (POLE)

AstraZeneca

Status: Completed

Conditions: Observational; Naturalistic

Study type: Observational

Funder types: Industry

Identifiers

NCT00745966

NIS-NKR-SER-2008/1

Details and patient eligibility

About

The purpose of this study is to reassure the clinical study data on atypical antipsychotics effect on quality of life in Korean Bipolar patients.

Enrollment: 1,000 estimated patients

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• The patient and the patient's legal representative (if any) must understand the nature of the study and must have given written consent.
• Meet DSM-IV-TR criteria for bipolar disorder (bipolar I disorder, bipolar II disorder) at the time of baseline.

Exclusion criteria

• Serious or unstable, medical illness. Subjects with chronic illness may be included but must be stable and otherwise physically healthy on the basis of a physical examination, medical history.
• Known intolerance for or lack of response to atypical antipsychotics , as judged by the investigator.